Cortical and Subcortical Dysmetabolism Are Dynamic Markers of Clinical Disability and Course in Anti-LGI1 Encephalitis

Eero Rissanen, MD, PhD, Kelsey Carter, MSN, CNP, Steven Cicero, BS, John Ficke, BA, Marie Kijewski, DSc, Mi-Ae Park, PhD, Joseph Kijewski, BS, Emily Stern, MD, Tanja Chitnis, MD, David Silbersweig, MD, Howard L. Weiner, MD, Chun K. Kim, MD, Jennifer Lyons, MD, Joshua P. Klein, MD, PhD, Shamik Bhattacharyya, MD, MS, and Tarun Singhal, MD, MBBS

Neurol Neuroimmunol Neuroinflamm 2022;9:e1136. doi:10.1212/NXI.0000000000001136

Abstract

Background and Objectives
This \[^{18}F\]fluorodeoxyglucose (FDG) PET study evaluates the accuracy of semiquantitative measurement of putaminal hypermetabolism in identifying anti–leucine-rich, glioma–inactivated-1 (LGI1) protein autoimmune encephalitis (AE). In addition, the extent of brain dysmetabolism, their association with clinical outcomes, and longitudinal metabolic changes after immunotherapy in LGI1-AE are examined.

Methods
FDG-PET scans from 49 age-matched and sex-matched subjects (13 in LGI1-AE group, 15 in non–LGI1-AE group, 11 with Alzheimer disease [AD], and 10 negative controls [NCs]) and follow-up scans from 8 patients with LGI1 AE on a median 6 months after immunotherapy were analyzed. Putaminal standardized uptake value ratios (SUVRs) normalized to global brain (P-SUVRg), thalamus (P/Th), and midbrain (P/Mi) were evaluated for diagnostic accuracy. SUVRg was applied for all other analyses.

Results
P-SUVRg, P/Th, and P/Mi were higher in LGI1-AE group than in non–LGI1-AE group, AD group, and NCs (all \(p < 0.05\)). P/Mi and P-SUVRg differentiated LGI1-AE group robustly from other groups (areas under the curve 0.84–0.99). Mediotemporal lobe (MTL) SUVRg was increased in both LGI1-AE and non–LGI1-AE groups when compared with NCs (both \(p < 0.05\)). SUVRg was decreased in several frontoparietal regions and increased in pallidum, caudate, pons, olfactory, and inferior occipital gyrus in LGI1-AE group when compared with that in NCs (all \(p < 0.05\)). In LGI1-AE group, both MTL and putaminal hypermetabolism were reduced after immunotherapy. Normalization of regional cortical dysmetabolism associated with clinical improvement at the 6- and 20-month follow-up.

Discussion
Semiquantitative measurement of putaminal hypermetabolism with FDG-PET may be used to distinguish LGI1-AE from other pathologies. Metabolic abnormalities in LGI1-AE extend beyond putamen and MTL into other subcortical and cortical regions. FDG-PET may be used in evaluating disease evolution in LGI1-AE.
Encephalitis associated with leucine-rich, glioma–inactivated-1 (LGII) protein autoantibodies is a form of autoimmune encephalitis (AE) in which the autoantibodies targeting LGII protein inflict a cascade of inflammatory changes affecting synaptic function and causing subsequent neuronal damage. LGII protein bridges the presynaptic voltage-gated potassium channel (protein Kv1.1 and the postsynaptic a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor by interacting with the postsynaptic ADAM23 and postsynaptic ADAM22 anchor molecules. Anti-LGII antibodies prevent the binding of LGII to ADAM23 and ADAM23, resulting in decreased density of both Kv1.1 and AMPA receptors and giving rise to neuronal hypexcitability and reduced neuronal plasticity. LGII-AE commonly affects middle-aged and elderly individuals, and the typical symptoms include subacute memory impairment, confusion, and seizures. The stereotypical facio-brachial dystonic seizures (FBDSs) are considered a diagnostic clue for LGII-AE, although present only in approximately half of the patients.

Early recognition, diagnosis, and rapidly started immunotherapy are necessary for improving prognosis in patients with LGII-AE. However, an initial diagnosis of LGII-AE can be missed or considerably delayed in most patients because of a low clinical index of suspicion. LGII-AE is overrepresented in elderly individuals (older than 60 years) when compared with other forms of AE and may be mistaken for Alzheimer disease (AD) or other dementias. An initial MRI finding may indicate AE but requires further confirmation. Furthermore, standard inflammatory workup from CSF can be normal, and results from specific AE-associated autoantibody screening could take several days to return in clinical practice.

PET imaging of brain metabolism with $[^{18}F]$-fluorodeoxyglucose (FDG) may be more sensitive and specific than MRI in identifying patients with LGII-AE. Putaminal and medial temporal hypermetabolism have been reported as the prominent metabolic abnormalities in anti–LGII-AE, but the accuracy of FDG-PET in distinguishing patients with LGII-AE from patients with other autoimmune encephalopathies and neurodegenerative conditions is not clear. Finally, apart from a few recent case series with a short follow-up duration, longitudinal metabolic changes and their clinical relevance in LGII-AE has not been systematically studied.

The primary research questions of this study are as follows: (1) to evaluate the accuracy of semiquantitative brain FDG-PET analysis in differentiating LGII-AE group from non-LGII-AE group, AD group, and from controls without known neurologic disease, (2) to determine the extent of metabolic changes in cortical and subcortical regions beyond the previously reported putaminal and mediotemporal lobe (MTL) abnormalities, and (3) to evaluate longitudinal changes in brain metabolism after immunosuppressive treatment in LGII-AE and their association with concurrent clinical disability and long-term clinical outcome.

**Methods**

**Participants**

A total of 57 FDG-PET scans in 49 individuals were identified retrospectively by performing a database search for patients who had undergone brain or whole body FDG-PET between 2008 and 2019 and based on individual clinicians’ referrals. Encephalitis, limbic, autoimmune, LGII, and encephalopathy were used as search terms to identify patients suspected of AE. Early recognition, diagnosis, and rapidly started immunotherapy are necessary for improving prognosis in patients with LGII-AE.

**Participants**

Of the 55 individuals, 28 patients with AE fulfilling the Graus 2016 criteria were identified as antibody-positive LGII-AE group (n = 13) or non–LGII-AE group (n = 15). Of the patients with LGII-AE, 8 had a follow-up FDG-PET performed on a median 5.7 (interquartile range [IQR] 6.5) months after the baseline PET. Age-matched and sex-matched patients with diagnosis of probable AD (n = 11) were included as positive controls with an alternate, known primary brain disorder that can mimic LGII. Similarly, a cohort of age-matched and sex-matched individuals without known primary neurologic or neuropsychiatric disease or structural brain abnormality, for whom a whole body
FDG-PET (including brain) had been performed for a non-neurologic indication (treatment planning or restaging of cutaneous malignancies), were included as negative controls (NCs, n = 10).

The non–LGI1-AE group included 4 patients with anti–NMDA receptor AE, 1 with anti–gamma-aminobutyric acid (GABA)-B receptor AE, 1 with anti–CASP2-AE, 2 with anti–GAD65-AE, 1 with anti–Zic4/GAD65-AE, 1 with anti–Hu-AE, 3 with Hashimoto encephalopathy (HE), 1 with Sjögren syndrome (SS), and 1 with antiphospholipid syndrome (APS)-associated AE. AD diagnoses were confirmed by FDG-PET and neuropsychologic testing and/or CSF analyses (amyloid-beta-42, total tau, and phosphorylated tau). Demographics of the study subjects are presented in eTable 1, links.lww.com/NXI/A695.

Longitudinal Clinical Follow-up
Clinical, MRI, and EEG data were extracted for all subjects in LGI1-AE and non–LGI1-AE groups. The level of clinical disability for those in LGI1-AE group at baseline (at first FDG-PET), short-term follow-up (at the time of follow-up FDG-PET), and long-term follow-up (at the latest clinical FDG-PET) was determined using modified Rankin scale (mRS). Disability at baseline was stratified into mild-to-moderate (mRS ≤ 3) or into at least moderately severe (mRS > 3) because of the patients’ high level of disability at that time. Clinical short-term and long-term outcomes were stratified into good (none-to-mild disability; mRS ≤ 2) and poor (at least moderate disability; mRS > 2) outcomes based on mRS at respective time points. The median (range) time of the long-term clinical follow-up was 19.7 (0.7–41.0) months.

Standard Protocol Approval
This retrospective, investigator-initiated academic study was conducted at Brigham and Women’s Hospital (BWH; Boston, MA). The study protocol was approved by the Institutional Review Board at BWH. Being a retrospective study using data acquired during routine clinical care, it was exempt from the requirement to obtain informed consent from study subjects.

[^18F]FDG-PET Imaging and Image Analyses
[^18F]FDG radiopharmaceutical production and FDG-PET imaging were performed according to BWH’s standard clinical procedures. PMOD Neuro Tool (PNEURO) 3.8 platform (PMOD Technologies, Zurich, Switzerland) was used for processing and analyzing the brain FDG-PET images.

Segmentation of regions of interest (ROI) was performed with automated anatomical labeling (AAL) template within the PNEURO utilities suite. The mean standardized uptake values (SUVs) were extracted for putamen (average of right and left) and MTL (combined right and left averages of hippocampus, amygdala, and parahippocampus). SUVs were also obtained for other supratentorial and brainstem ROIs based on the AAL template.

For semiquantitative analyses, normalizations of SUVs from target region were performed for global brain (volume-weighted average SUV of all AAL template brain ROIs including white matter), thalamus (average SUV of right and left), and midbrain ROIs. Thus, the following FDG-PET indices were acquired for primary analyses: putaminal global brain normalized SUV ratio (P-SUVr), putamen-to-thalamus ratio (P/Th), putamen-to-midbrain ratio (P/Mi), MTL-SUVr, MTL/Th, and MTL/Mi for mediotemporal lobe. Both global and thalamic normalizations are standard techniques used routinely in brain FDG imaging. Global normalized SUVrgs were also obtained for the remaining AAL ROIs. Image analyses were performed blinded to the patients’ disease severity (mRS status).

Statistical Methods
Demographics were compared between groups using the Fisher exact and Kruskal-Wallis tests. Differences in FDG-PET parameters between LGI1-AE, non–LGI1-AE, AD and NC groups were evaluated using the Kruskal-Wallis test with Bonferroni correction. For subgroup analyses, patients in non-LGI1 group were further grouped into patients with NMDA receptor AE (n = 4), other limbic encephalitis (LE)-like-AEs (LE-like-AE: with GABA-B, CASPR2, anti-Hu, or GAD65-antibodies; n = 6), and LE-like-AE associated with other autoimmune systemic disorders (LE: SS, HE, and APS; n = 5). Longitudinal changes in mRS scores in LGI1-AE group were evaluated using the Friedman Test. For the LGI1-AE subgroup with follow-up FDG-PET, changes in FDG uptake from baseline to follow-up were evaluated with the Wilcoxon signed rank test, and comparisons of FDG-PET indices at baseline and follow-up against NCs were performed using the Mann-Whitney U test. Performance of the FDG-PET indices in differentiating LGI1-AE group from other groups was evaluated with receiver operating characteristic (ROC) curve analysis. A comparison of ROC area under the curve (AUC) between FDG-PET indices was performed with DeLong26 statistics. Using the ROC curve coordinates, cutoff values for optimal sensitivity and specificity for the FDG-PET indices were evaluated by identifying the highest Youden index (J = sensitivity + specificity − 1). If 2 equal J values were observed, the one with higher sensitivity was chosen. Positive and negative likelihood ratios (LR+ and LR−) were calculated for the cutoff values. The p values < 0.05 were regarded statistically significant, unless stated otherwise. IBM SPSS Statistics, version 24.0 (IBM Corp., Armonk, NY) was used for all statistical analyses except for comparison of AUCs, where MedCalc Statistical software, version 19.5.2 (MedCalc Software Ltd, Ostend, Belgium) was used.

Statistical parametric mapping (SPM; SPM12 software, Wellcome Centre for Human Neuroimaging, London, UK) was used for voxel-wise evaluation of parametric SUVr images for those with LGI1-AE. PET images were stereotactically normalized to the Montreal Neurologic Institute template. Differences in baseline SUVr in LGI1-AE patients with good vs poor long-term outcome were compared with
independent $t$ test. Paired $t$ test was applied to evaluate longitudinal metabolic changes from baseline to short-term follow-up PET in patients with different levels of disability at the follow-up PET. Parametric $t$ statistic maps visualizing voxels with significant correlations, group differences, and within-group changes were produced.

**Data Availability**

Any anonymized data not provided in this article will be shared on request from any qualified investigator for procedure and result replication purposes.

**Results**

**Clinical Characteristics**

Detailed clinical characteristics of those in LGI1-AE and non–LGI1-AE groups are listed in Tables 1 and 2. The median (range) time from symptom onset to the first [$^{18}$F]FDG-PET scan was 3.2 (0.2–13.7) months for the LGI1-AE and 3.2 (0.4–36.6) months for the non–LGI1-AE groups ($p = 0.786$). Generalized tonic–clonic seizures were observed in 31% (4/13) in the LGI1-AE and in 40% (6/15) in the non–LGI1-AE groups ($p = 0.705$).

Among patients with LGI1-AE, 69% (9/13) presented with unilateral or bilateral FBDSs, and cognitive impairment was observed in all subjects. Regarding clinical disability at the time of first FDG-PET, the median (range) mRS score was 4 (1–5) (Table 1).

**Conventional Imaging and EEG Findings**

On visual interpretation, all baseline FDG-PET scans in LGI1-AE and non–LGI1-AE groups were abnormal. In LGI1-AE group, MRI findings showed either cortical, mesiotemporal, or putaminal hyperintensity in 8 of the 13 (62%) cases, whereas an additional 3 cases showed nonspecific white matter abnormalities (Table 1). The rate of EEG abnormalities was not different between LGI1-AE and non–LGI1-AE groups (8/12, 67% vs 11/12, 92%; $p = 0.317$). Similarly, there was no difference in the proportion of patients receiving immunosuppressive and antiseizure treatment (23% vs 47%, 69% vs 47%, $p = 0.254$; 69% vs 47%, $p = 0.276$, respectively) at the time of the first FDG-PET in LGI1-AE vs non–LGI1-AE groups. Further details regarding MRI and EEG abnormalities and treatment in both LGI1-AE and non–LGI1-AE groups are presented in Tables 1 and 2.

**Putaminal Hypermiselation in LGI1-AE**

Increased putaminal metabolic activity was observed in LGI1-AE group when compared with all other groups (i.e., non–LGI1-AE group, AD group, and NCs) with all the putaminal indices ($p < 0.001$ for P-SUVRg, $p = 0.002$ for P/Th, and $p < 0.001$ for P/Mi). On pair-wise comparisons, LGI1-AE group exhibited increased P-SUVRg, higher P/Th, and higher P/Mi values when compared with non–LGI1-AE group (+13.8%, $p = 0.014$ for P-SUVRg; +14.1%, $p = 0.010$ for P/Th, and +18.8%, $p = 0.001$ for P/Mi). Similarly, P-SUVRg, P/Th, and P/Mi were higher in LGI1-AE group in comparison with NCs (+19.8%, $p < 0.001$ for SUVRg; +16.0%, $p = 0.004$ for P/Th, and +14.6%, $p = 0.009$ for P/Mi) (Figure 1A, eTable 2, links.lww.com/NXI/A695). In non–LGI1-AE subgroup analyses, P-SUVRg and P/Mi ratio were higher in LGI1-AE when compared with NMDA receptor AE, and all 3 putaminal indices were higher in LGI1-AE when compared with other LE-like-AEs (eTable 3).

When compared with AD group, LGI-AE group demonstrated higher P-SUVRg, P/Mi, and P/Th-values, but only the differences in P/Mi achieved statistical significance (+15.7%, $p = 0.001$ for P/Mi; +12.7%, $p = 0.131$ for SUVRg, and +9.5%, $p = 0.076$ for P/Th) (Figure 1A, eTable 2, links.lww.com/NXI/A695). The ROI-based, semiquantitative findings of abnormal putaminal metabolism were consistent with individual visualization using parametric SUVRg images (Figure 1C). No differences were observed in the putaminal indices between patients with LGI1-AE with or without FBDS at the time of the initial FDG-PET.

**Mediotemporal Hypermiselation in Both LGI1-AE and Non–LGI1-AE Groups**

There were no differences between LGI1-AE and non–LGI1-AE groups or non–LGI1-AE subgroups in the MTL indices. However, abnormally increased MTL index values were seen in both LGI1-AE and non–LGI1-AE groups when compared with NCs (Figure 1B, eTables 2–3, links.lww.com/NXI/A695).

Specifically, higher MTL-SUVRg, MTL/Th, and MTL/Mi values were observed in LGI1-AE group when compared with NCs (+16.5%, $p = 0.008$; +11.1%, $p = 0.048$ and +10.2%, $p = 0.033$, respectively). Similarly, in non–LGI1-AE vs NC comparison, MTL-SUVRg and MTL/Th values were higher in non–LGI1-AE group than those in NCs (+14.7%, $p = 0.003$ and +11.9%, $p = 0.016$, respectively).

When compared with AD group, both LGI1-AE and non–LGI1-AE groups exhibited higher MTL/Mi values (+12.0%, $p = 0.001$ for LGI1 vs AD and +10.5%, $p = 0.014$ for non-LGI1 vs AD) (Figure 1B, eTable 2, links.lww.com/NXI/A695). No differences were observed in the MTL indices when comparing patients with LGI1-AE with or without FBDS at the time of the initial FDG-PET.

**Putamen-to-Midbrain Ratio Best Differentiates LGI1-AE Group From Other Groups**

On ROC analyses, all 3 putaminal indices provided significant differentiation for distinguishing patients with LGI1-AE from NCs, non–LGI1-AE group, and AD group (all $p < 0.05$) (Figure 2A). There were no differences in the ROC AUCs between P-SUVRg, P/Mi, and P/Th values in any of the group comparisons ($p = ns$ for all). However, when evaluated for optimal accuracy, P-SUVRg provided the best combination of sensitivity and specificity (manifesting as the highest absolute Youden J values at the index-specific cutoff values) of the 3 putaminal indices for the comparison of LGI1-AE group vs NCs, and P/Mi provided the highest absolute J values for
### Table 1: Demographic, Clinical, Antibody Testing, MRI, and EEG Characteristics of the LGI1-AE Group

<table>
<thead>
<tr>
<th>Case No.</th>
<th>Age/sex</th>
<th>LGI1-antibody test result</th>
<th>Clinical presentation before first PET</th>
<th>Time from onset to first PET (time to follow-up PET) (mo)</th>
<th>MRI at the time of first PET</th>
<th>EEG at the time of first PET</th>
<th>Immunomodulatory treatments</th>
<th>Neurology follow-up time.a</th>
<th>Clinical outcome (mRS), other notable</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>77/M</td>
<td>S-LGI1-Ab positive</td>
<td>R-dominant FBDS, cognitive impairment (mRS 4).</td>
<td>1.3 (9.3)</td>
<td>Normal</td>
<td>B/L cerebral T2 hyperintensity</td>
<td>IvMP, IvIg x2, PoP, RTX x3</td>
<td>41 months. Recovered fully (mRS 0)</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>51/F</td>
<td>N/A (VGKC positive in 2008)</td>
<td>Cognitive impairment, left facial twiching, and GTC seizure, Thyroid papillary microcarcinoma. (mRS 3)</td>
<td>4.2 (1.2)</td>
<td>B/L mediocortical T2 hyperintensity</td>
<td>Bitemporal dysfunction w/ cortical irritabilityb</td>
<td>Ivlg, PoP, PLEX, CP x7</td>
<td>37 months. Partial recovery, mildly impaired short-term memory (mRS 1); St. postthyreoidectomy</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>57/M</td>
<td>CSF-LGI1-Ab positive</td>
<td>Episodic epigastric sensations w/ speech difficulty, R FBDS, Confusion and memory decline (mRS 4).</td>
<td>4.9 (N/A)</td>
<td>L mediocortical T2 hyperintensityd</td>
<td>Normalb</td>
<td>IvMP, RTX x4, PoP</td>
<td>18 months. Partial recovery; mild cognitive impairment (mRS 1)</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>74/M</td>
<td>S-LGI1-Ab positive</td>
<td>Subclinical seizures, confusion, memory loss, and speech difficulties (mRS 4).</td>
<td>0.8 (N/A)</td>
<td>Unrelated microvascular changes</td>
<td>Left temporal epileptic dischargesb</td>
<td>IvMP, PoP, Ivlg x4, RTX x2</td>
<td>30 months. Mild residual behavioral changes (mRS 1)</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>48/M</td>
<td>S- and CSF-LGI1-IgG-Ab positive</td>
<td>Memory decline, personality change, GTC, and partial seizures (mRS 4).</td>
<td>0.6 (5.6)</td>
<td>L mediocortical T2 hyperintensityd</td>
<td>Left temporal epileptic discharges b</td>
<td>IvMP, Ivlg, PoP, RTX x3</td>
<td>25 months. Recovered fully (mRS 0)</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>75/F</td>
<td>S-LGI1-Ab positive</td>
<td>R FBDS, cognitive decline (mRS 3).</td>
<td>2.3 (5.3)</td>
<td>Normal</td>
<td>Right temporal epileptic dischargesb</td>
<td>IvMPb x3, PoP, PLEX, RTX x3</td>
<td>24 months. Partial recovery; mild cognitive issues (mRS 1). Invasive mamma-ca operated</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>63/M</td>
<td>S-LGI1-Ab positive</td>
<td>LBDS, SIADH, mild memory decline (mRS 4).</td>
<td>0.2 (11.6)</td>
<td>Unrelated vascular compression</td>
<td>Normalb</td>
<td>IvMP, Ivlg x5, RTX x3, PoP</td>
<td>12 months. Relapsed x2, improved (mRS 1), lost to further follow-up</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>57/M</td>
<td>S-LGI1-Ab positive</td>
<td>R FBDS, GTC seizure, episodic confusion, abulia, fasciculations, and ataxia (mRS 4).</td>
<td>3.2 (0.5)</td>
<td>Unrelated microvascular changes</td>
<td>Normal</td>
<td>IvMP, Ivlg x5, PoP, PLEX, RTX x3</td>
<td>20 months. Recovered fully (mRS 0)</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>65/M</td>
<td>S-LGI1-Ab positive</td>
<td>Rapidly progressive dementia, hypotonia, and L FBDS (mRS 4).</td>
<td>8.1 (N/A)</td>
<td>L mediocortical T2 hyperintensity w/Gd+</td>
<td>Mild L &gt; R cerebral dysfunctionb</td>
<td>Ivlgb, IvMPb, PoP, RTX x1</td>
<td>24 months. Partial recovery, mild to moderate memory impairment, and requires some help (mRS 3)</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>78/M</td>
<td>S-LGI1-IgG-Ab positive</td>
<td>Right FBDS, mild memory decline (mRS 1).</td>
<td>5.4 (N/A)</td>
<td>L pulaminal T2 hyperintensity w/diffusion restriction</td>
<td>Normal</td>
<td>IvMPb x9, PoP</td>
<td>21 d. Improved; memory impairment (mRS 1). Lost to further follow-up</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>65/F</td>
<td>S- and CSF-LGI1-IgG-Ab positive</td>
<td>LBDS, atonic seizures, memory decline (mRS 4).</td>
<td>1.0 (N/A)</td>
<td>R medio-temporal Gd+</td>
<td>Bitemporal epileptic discharges</td>
<td>IvMPb, Ivlgb, PoP, RTX x2</td>
<td>13 months. Recovered fullyb (mRS 0)</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>70/F</td>
<td>S- and CSF-LGI1-IgG-Ab positive</td>
<td>B/L FBDS, cognitive decline, seizures, hypotonia, choreiform movements, and impaired balance (mRS 5).</td>
<td>13.7 (5.8)</td>
<td>B/L restricted cortical diffusion, cerebellar Gd+</td>
<td>Left frontotemporal dysfunctionb</td>
<td>IvMP, PoP, RTX x2</td>
<td>13 months. Recurring disease activity. Improved; memory impairment, impulsivity, and in assisted living (mRS 3)</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>70/F</td>
<td>S-LGI1-IgG-Ab positive</td>
<td>Cognitive decline, short-term memory loss, auditory hallucinations, and hypotonia (mRS 4).</td>
<td>8.4 (7.0)</td>
<td>B/L mediocortical T2 hyperintensity</td>
<td>Normal</td>
<td>IvMP, RTX x5</td>
<td>19 months. Improved; mild forgetfulness and impulsivity, and anger issues (mRS 1)</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: α3-ACHR = ganglionic alpha 3–acetylcholine receptor; Ab = antibody; AE = autoimmune encephalitis, APS = antiphospholipid syndrome; B/L = bilateral; CP = cyclophosphamide; D-5MP-PNP = demyelinating sensorimotor polyneuropathy; FDG = [18F]fluorodeoxyglucose; FBDS = facio-brachial dystonic seizure; Gd+ = Gadolinium enhancement; GTC = generalized tonic-clonic; HE = Hashimoto encephalopathy; IvMP = IV methylprednisolone (1 g daily for 3–5 days); Ivlg = IV Immunoglobulin (doses ranging from 1.0 to 2.0 g/kg over 2–5 days); L = left; LGI1 = Leucine-rich, glioma inactivated-1; mRS = modified Rankin scale; PLEX = plasma exchange (5 cycles); PoP = peroral prednisone, tapered; R = right; RTX = IV rituximab (1,000 mg infusion); S = serum; VGKC = voltage-gated potassium channel.

N.B. The Number of Treatment Cycles (for IvMP or Ivlg) or infusions (for RTX) marked, for example, x2.

* Follow-up time reported as the time from the first [18F]FDG PET scan to the latest available neurologic follow-up.

+ Antiepileptic medication in use at the time of the first [18F]FDG PET scan.

b An MRI performed before this baseline MRI had been normal.

c The marked immunosuppressive medication already given or initiated at the time of the first [18F]FDG PET scan.

* Neurology follow-up ongoing.
<table>
<thead>
<tr>
<th>Case no</th>
<th>Age/sex</th>
<th>Diagnosis, antibody test result</th>
<th>Clinical presentation before the first PET</th>
<th>Time from onset to first PET (mo)</th>
<th>MRI at the time of first PET</th>
<th>EEG at the time of first PET</th>
<th>Immunomodulatory treatments</th>
<th>Neurology follow-up time</th>
<th>Other notable</th>
</tr>
</thead>
<tbody>
<tr>
<td>14</td>
<td>18/F</td>
<td>NMDA-r AE CSF- and S-NR1/- NR2-Ab positive</td>
<td>Psychosis, catatonia, fever, GTC and focal seizures</td>
<td>0.5</td>
<td>Unrelated nonspecific subcortical white matter changes</td>
<td>Generalized slowing(^a)</td>
<td>Salpingo-oophorectomy, PLEX x5, lIg x1</td>
<td>11 months. Near full recovery; mild decline in neuropsychologic testing (\pm) expected baseline</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>24/F</td>
<td>NMDA-r AE CSF- and S-NR1-Ab positive</td>
<td>Psychosis, dysautonomia, oral dyskinesia/ automatism, and malignant catatonia</td>
<td>0.9</td>
<td>B/L mediotemporal and subinsular hyperintensity in FLAIR</td>
<td>Diffuse slowing</td>
<td>lIg x1, lIg x1, B/L oophorectomy</td>
<td>2 months. Near full recovery; residual anxiety</td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>62/F</td>
<td>NMDA-r AE CSF- and S-NMDA-r Ab positive</td>
<td>Headache and short-term memory deficit</td>
<td>2.0</td>
<td>B/L mediotemporal (L &gt; R) T2 hyperintensity w/leptomeningeal Gd+</td>
<td>Bitemporal L &gt; R slowing</td>
<td>lIg x1</td>
<td>17 d. Partial recovery; daily headaches and some memory deficits</td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>70/M</td>
<td>NMDA-r AE CSF-NMDA-r-Ab positive</td>
<td>LUE jerking and clumsiness, weight loss, subacute memory impairment, and fatigue</td>
<td>3.2</td>
<td>R basal ganglia, R mediotemporal, and B/L hippocampal Gd+. Central sulcus FLAIR hyperintensity w/leptomeningeal Gd+</td>
<td>Normal(^b)</td>
<td>lIg x7, lIg x1, lIg x6</td>
<td>8 months. Near full recovery; no symptoms while still on PaP at follow-up</td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>59/F</td>
<td>SS-associated AE S-Ro-Ab 190 EU/mL, S-La-Ab 119 EU/mL</td>
<td>Seizures, memory loss</td>
<td>0.4</td>
<td>B/L mesial temporal T2 hyperintensity</td>
<td>Numerous bitemporal discharges(^c)</td>
<td>lIg x1</td>
<td>27 months. Partial recovery; persistent short-term memory impairment</td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>74/M</td>
<td>HE S-TPO-Ab 787 IU/mL</td>
<td>Depression with psychotic features, anxiety, and dementia</td>
<td>11.8</td>
<td>Normal</td>
<td>B/L slowing</td>
<td>lIg x1, PaP</td>
<td>10 months. Mild improvement; remaining memory decline and impulsivity</td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>62/F</td>
<td>HE S-TPO-Ab 339.6 IU/mL</td>
<td>Confusion, headache, expressive aphasia, and GTC seizures</td>
<td>3.5</td>
<td>L posterior temporal WM FLAIR abnormality w/low diffusivity and Gd+</td>
<td>L temporal epileptic discharges(^d)</td>
<td>lIg x1, PaP</td>
<td>49 months. Partial recovery; mild cognitive impairment, suspicion of underlying neurodegenerative disorder but no progression</td>
<td></td>
</tr>
<tr>
<td>21</td>
<td>68/F</td>
<td>HE S-TG-Ab 353.5 IU/mL</td>
<td>Seizures, nonfuent expressive aphasia, hyperreflexia, ocular clonus; and severe pneumonia</td>
<td>13.0</td>
<td>Normal</td>
<td>Multifocal epileptic discharges(^d)</td>
<td>lIg x1, PaP, lIg x1, lIg x1</td>
<td>34 months. Relapse w/paranoia, visual hallucinations. Partial recovery; and mild cognitive impairment</td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>63/M</td>
<td>Anti-Zic4/GAD65 AE S-Zic4-Ab and S-GAD-65-Ab positive</td>
<td>Ataxia, tremor, dysphagia, dysarthria; and small cell lung cancer</td>
<td>9.6</td>
<td>Numerous unrelated nonspecific WM changes</td>
<td>N/A</td>
<td>lIg x1 (+dexamethasone, carboplatin, and etoposide)</td>
<td>5 d. Stable but persisting neurologic symptoms with no improvement</td>
<td></td>
</tr>
<tr>
<td>23</td>
<td>64/M</td>
<td>Anti-GAD-65 AE S-GAD-Ab 0.23 nmol/L</td>
<td>Opsodunosus myoclonus, limb ataxia and dysmetria, upbeat nystagmus, dysphagia; PE, suspicion of lung malignancy</td>
<td>4.2</td>
<td>Unrelated ischemic WM changes</td>
<td>N/A</td>
<td>lIg x1, mycophenolate, PaP, lIg x1, lIg x1</td>
<td>5 months. Partial initial recovery. New episode w/worsening symptoms and delirium; remaining, opsodunosus, mild delirium, mild dysarthria, and dysmetria</td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>66/F</td>
<td>Anti-Hu AE S-Hu-Ab positive</td>
<td>Seizures, lethargy, confusion, reduced consciousness; and small cell lung cancer</td>
<td>2.3</td>
<td>Mild L mediotemporal hyperintensity</td>
<td>Multifocal L &gt; R epileptic discharges(^e)</td>
<td>lIg x1, lIg x1, PaP</td>
<td>15 d. Mild improvement, but later progressed; and deceased after latest neurology follow-up</td>
<td></td>
</tr>
<tr>
<td>25</td>
<td>77/M</td>
<td>APS-associated AE S-Beta-2-glycoprotein I Ab &gt;150 U/mL(^a)</td>
<td>Progressive cognitive decline, mood changes, chorea and mild tremor, dysphagia, oromandibular dyskinesia; and multiple previous strokes</td>
<td>36.6</td>
<td>Multiple microvascular WM changes; old infarcts in cerebellum, R occipital lobe, R centrum semiovale, and L thalamus</td>
<td>N/A</td>
<td>No immunomodulatory treatment (warfarine initiated)</td>
<td>15 months. Partial recovery at latest neurology follow-up; deceased later due to acute metabolic encephalopathy and aspiration pneumonia</td>
<td></td>
</tr>
<tr>
<td>26</td>
<td>70/F</td>
<td>Anti-GAD-65 and D-SM-PNP-associated AE S-GAD-65 and S-O3-ACNR-Ab positive</td>
<td>Confusion and progressive weakness of upper and lower limbs</td>
<td>0.9</td>
<td>Unrelated old L frontal ischemic infarct and unrelated microvascular WM changes</td>
<td>Bilateral slowing</td>
<td>lIg x1</td>
<td>3 months. Full cognitive recovery, peripheral neuropathic pain remained</td>
<td></td>
</tr>
</tbody>
</table>

Continued
Several additional subcortical structures, including caudate, pallidum, and pons, demonstrated hypermetabolism in LGI1-AE group when compared with NCs (+7.3 to +12.5, all p < 0.05; Figure 3B, eTable 5, links.lww.com/NXI/A695). None of these additional cortical or subcortical structures showed associations between baseline mRS and their respective SUVRg values.

**Metabolic Changes in LGI1-AE After Immunosuppressive Treatment and Their Relationship With Short-Term Outcomes**

All patients with LGI1-AE received immunosuppressive treatment, and short-term follow-up FDG-PET images were available for 8 patients with LGI1-AE (Table 1). The mRS scores reduced from baseline to short-term follow-up (from median [IQR] mRS 4 [2] to 2 [2]; p = 0.008) (eFigure 1, links.lww.com/NXI/A695).

**Normalization of Mediotemporal Hypermetabolism After Treatment**

MTL-SUVRg decreased on follow-up in LGI1-AE (−11.3%, p = 0.050, significant at p = 0.050) and was no longer higher than that in NCs at follow-up (p = 0.829) (Figure 4A, eTable 6, links.lww.com/NXI/A695).

Of importance, patients with good short-term outcome (mRS ≤ 2) at the time of follow-up PET showed a reduction in MTL hypermetabolism (−19.8%, p = 0.043), as opposed to those with a poorer short-term outcome (mRS > 2), who did not show changes (+6.0%, p = 1.000) when compared with their baseline. Furthermore, on comparing patients with mRS > 2 with patients with mRS ≤ 2, the former demonstrated higher follow-up SUVRg values (effect size −0.79, p = 0.036) at the time of follow-up PET (eFigure 2, eTable 7, links.lww.com/NXI/A695). Individual changes in mediotemporal metabolism are visualized for case 5 in Figure 4B. Changes in MTL/Th and
MTL/Mi values after immunotherapy are depicted in Figure 4A and summarized in eTable 6, links.lww.com/NXI/A695.

### Changes in Putaminal Hypermetabolism After Treatment

Significant reduction in putaminal uptake at follow-up was observed for SUVRg in LGI1-AE group (−11.2%; *p < 0.012), but it remained higher than that in NCs (+10.1%; *p = 0.013) (Figure 4A, eTable 6, links.lww.com/NXI/A695). Of interest, when stratified by short-term clinical outcome, P-SUVRg reduced from baseline to follow-up in the mRS ≤ 2 group (−12.5%, *p = 0.043) but not in the mRS > 2 group (−9.9%, *p = 0.109). However, short-term follow-up PET did not demonstrate differences in putaminal metabolism between the good and poor short-term outcome groups (effect size −0.26, *p = 0.036) (eFigure 2, eTable 7, links.lww.com/NXI/A695). Individual putaminal metabolic changes are demonstrated in case 6 in Figure 4C. Changes in P/Th and P/Mi after immunosuppressive treatment are shown in Figure 4A and summarized in eTable 6, links.lww.com/NXI/A695.

---

**Figure 1 Regional [18F]FDG-PET Findings in LGI1- and Non-LGI1 AE Groups, Alzheimer Disease Group, and NCs**

Metabolic activity in (A) putamen and (B) MTL, measured as standardized uptake value ratios (SUVR) normalized to global brain, thalamus and midbrain. (C) Visualization of metabolic abnormalities in individual patients in LGI1-AE and non-LGI1-AE groups using parametric, global normalized [18F]FDG SUVR images. The images represent patients with LGI1-AE (case 6), NMDAr (case 16), and APS-associated (case 25) autoimmune encephalitides (AE) and demonstrate putaminal hypermetabolism and relative occipital hypermetabolism in LGI1-AE, lateral occipital hypometabolism in NMDAr-AE, and pronounced putaminal hypermetabolism in APS-AE. Numbering of the patient cases refers to the case numbers in Tables 1 and 2. *p < 0.05 and **p < 0.01 (significant at the level of *p < 0.05). [18F]FDG = [18F]fluorodeoxyglucose; AD = Alzheimer disease; AE = autoimmune encephalitis; APS = antiphospholipid syndrome; LGI1 = leucine-rich, glioma-inactivated-1; Mi = midbrain; MTL = mediotemporal lobe; NC = negative control; Non-LGI1 = non-LGI1 autoimmune encephalitis; P = putamen; SUV = standardized uptake value; SUVRg = global brain normalized standardized uptake value ratio; Th = thalamus.
Changes in Metabolism in Neocortical and Other Gray Matter Regions

Significant increases were observed in cortical metabolism after treatment and were associated with concurrent short-term clinical improvement. Specifically, cortical SUVRg values increased in frontal (middle and opercular part of inferior frontal), occipital (posterior cingulum, calcarine, cuneus, lingual; superior, middle, and inferior occipital), and parietal (inferior parietal and angular) regions ($p = 0.043$ for all) in those who improved to mRS $\leq 2$ at short-term follow-up PET, whereas SUVRg values remained unchanged in the mRS $> 2$ group (eFigure 3, links.lww.com/NXI/A695).

On exploratory SPM analysis, patients with LGI1-AE who improved to mRS $< 2$ showed increased cortical metabolic activity from baseline to follow-up, whereas those who had persistent disability (mRS $> 2$) at the time of follow-up PET did not and, in fact, showed further worsening of cortical metabolism in some areas (Figure 5A).

Relationship of Initial Metabolic Abnormalities With Long-Term Outcome in LGI1-AE

At the median long-term follow-up of 19.7 months, 31% of the patients with LGI1-AE were asymptomatic, and of the remaining 69% who had residual symptoms, cognitive symptoms were present among all (Table 1). The median mRS reduced from 4 at the time of baseline PET to 1 at the time of their last clinical follow-up ($p = 0.001$) (eFigure 1, links.lww.com/NXI/A695). There was a nonsignificant trend for patients with long-term mRS $> 2$ to have longer time gap from symptom onset to baseline PET when compared with patients with mRS $\leq 2$ (time [range]: 10.9 [8.1–13.7] vs 2.3 [0.2–8.4] months; $p = 0.051$) (Figure 5C).
SPM analysis revealed that orbital frontal and cingulate gyrus metabolic activity was lower in the group of patients with worse long-term outcome (mRS > 2) at the last clinical follow-up (peak uncorrected $p < 0.01$) than in patients with better long-term outcome (mRS \(\leq 2\)) (Figure 5B). Moreover, on ROI analyses, baseline SUVRg was lower in anterior and middle cingulate in the long-term mRS > 2 group when compared with the mRS \(\leq 2\) group (−12.5% and −6.9%; \(p = 0.026\) for both) (eTable 8, links.lww.com/NXI/A695). No associations were observed between baseline mediotemporal or putaminal hypermetabolism and long-term clinical outcome (eTable 9, links.lww.com/NXI/A695).

**Classification of Evidence**
This study provides Class II evidence that semiquantitative measures of putaminal metabolism on PET can differentiate LGI1-AE group from non-LGI1-AE group, AD group, or NCs.

**Discussion**
Our study shows that semiquantitative FDG-PET indices of putaminal metabolism (P/Mi ratio and SUVRg) distinguished LGI1-AE group from non–LGI1-AE group, AD group, and NCs with high diagnostic accuracy. Furthermore, we reported the following in LGI1-AE group: (1) MTL-SUVRg associated with concurrent and short-term clinical disability changes; (2) widespread hypometabolism was seen in several neocortical regions, which improved in short term (approximately 6 months) among clinical responders; and (3) regional neocortical hypometabolism at initial presentation was associated with long-term clinical outcome in LGI1-AE group.

Basal ganglia, hippocampal formation, and amygdala are among the regions with highest LGI1 expression in human brain (Consensus Human brain data set, Human Protein Atlas; available at proteinatlas.org).\(^{[28-30]}\) Anti-LGI1 antibodies have been shown to decrease expression of potassium (Kv1.1) channels on neuronal cell membranes,\(^{[4]}\) which in turn is associated with neuronal hyperexcitability and hypermetabolism. \([^{[18F]}\)FDG concentrates in brain tissue in proportion to neuronal metabolic activity and is mediated by upregulation of glucose transporters and intracellular hexokinase enzyme, thus accounting for the hypermetabolic signal seen most prominently in putamen and MTL in anti–LGI1-AE patients.

Several previous studies have reported putaminal and mediotemporal hypermetabolism in LGI1-AE.\(^{[9,14,17,19,31-33]}\) Basal ganglia hypermetabolism was reported in 77% of patients with LGI1-AE and mediotemporal hypermetabolism in 62% of patients with LGI1-AE in a pooled cohort of 64 patients from 9 studies.\(^{[9]}\) However, only limited information is available about semiquantitative FDG-PET and its longitudinal implications in LGI1-AE. When compared with standard visual analyses, few studies have shown that semiquantitative

---

**Figure 3** Cortical and Subcortical Dysmetabolism Beyond Putamen and Mediotemporal Lobe in LGI1-AE

Comparison of brain metabolism in patients with LGI1-AE (n = 13) and NCs (n = 10) in (A) cortical and (B) subcortical regions of interest. *\(p < 0.05\), **\(p < 0.01\) (significant at the level of \(p < 0.05\)). \([^{[18F]}\)FDG = \([^{[18F]}\)fluorodeoxyglucose; AE = autoimmune encephalitis; Frontal Inf Oper = opercular part of inferior frontal gyrus; Frontal Inf Orb = orbital part of inferior frontal gyrus; Frontal Inf Tri = triangular part of inferior frontal gyrus; Frontal Med Orb = medial orbital part of superior frontal gyrus; LGI1 = leucine-rich, glioma-inactivated-1; NC = negative controls; occipital Inf = inferior occipital lobe; parietal Inf = inferior parietal lobe; SUVRg = global normalized standardized uptake value ratio.
Figure 4 Longitudinal Changes in Brain Metabolism After Immunosuppressive Treatment in Patients With LGI1-AE

(A) Individual and group-level changes in brain metabolism from baseline to short-term follow-up in LGI1-AE group (n = 8), measured with [18F]FDG PET indices in mediotemporal lobe and putamen and compared with NCs (n = 10). (B) Visualization of individual changes in brain metabolism after immunotherapy in 2 patients with LGI1-AE using parametric [18F]FDG SUVRg images. The images in (B) demonstrate decreases of the initial hypermetabolism in striatum (case 6) and mediotemporal lobe (case 5) and increases in occipital metabolism (both cases). The numbering of the LGI1 cases refers to the case numbers in Table 1.

* $p < 0.05$, ** $p < 0.01$ (both significant at the level of $p < 0.05$), # $p = 0.05$ (significant at the level of $p = 0.05$). [18F]FDG = [18F]fluorodeoxyglucose; AE = autoimmune encephalitis; LGI1 = leucine-rich, glioma–inactivated-1; Mi = midbrain; MTL = mediotemporal lobe; NC = negative control; P = Putamen; SUV = standardized uptake value; SUVRg = global brain normalized standardized uptake value ratio; Th = thalamus.
approaches with healthy control reference population further increase the sensitivity of FDG-PET to detect metabolic abnormalities in LGI1-AE or in cohorts of AE of mixed etiologies. Moreover, AD occurs in an age group similar to that in LGI1-AE, and visual analysis of FDG-PET images may be inadequate to distinguish AD from LGI1-AE owing to relative cortical hypometabolism in AD that can give an appearance of an increased FDG-PET uptake in basal ganglia. To the best of our knowledge, our study is the first to systematically evaluate semiquantitative FDG-PET indices in LGI1-AE group compared with non-LGI1-AE and AD groups and provide long-term clinical outcome data in relation to FDG-PET in patients with LGI1-AE.

Although all semiquantitative indices yielded a high accuracy (AUC > 0.8), P/Mi yielded the highest accuracy for all group comparisons. From a mechanistic standpoint, midbrain may be an optimal reference region for FDG-PET analysis in LGI1-AE because it has very low expression of LGI1-RNA and may be least affected by the auto-aggressive LGI1 antibodies. We propose that a P/Mi ratio cutoff value of >1.44–1.46 may be used to aid in early differential diagnosis of LGI1-AE. These cutoff values correspond to a positive likelihood ratio >10 and a negative likelihood ratio <0.20, emphasizing their high diagnostic accuracy, particularly in individuals with modest pretest probabilities of showing anti-LGI1-AE. This approach could assist in clinical decision-making while awaiting serum and CSF antibody results that could take several days to return in clinical practice, and especially if conventional brain MRI finding shows negative results. Although CSF-Tau, phospho-Tau, and amyloid-beta-42 evaluations may help distinguish AD from LGI1-AE, FDG-PET suggestive of LGI1-AE in patients otherwise suspected of AD should trigger antibody evaluations. Finally, the use of our proposed exact cutoffs for brain FDG-PET requires future confirmation in larger cohorts and across PET scanners with variable reconstruction algorithms and image processing approaches.

We also showed that mediotemporal hypermetabolism did not help distinguish LGI1-AE from non-LGI1-AE and was present in both LGI1-AE and non-LGI1-AE groups when compared with NCs. However, within the anti-LGI1-AE group, MTL hypermetabolism associated with the severity of concurrent clinical disability during the acute phase. Moreover, a reduction in MTL hypermetabolism tracked the degree of clinical
improvement at the time of follow-up PET (median 6 months from presentation). These findings emphasize the role of MTL pathology in manifestation of early clinical disability, likely mediated by the impact of MTL dysfunction on both seizure occurrence and cognitive impairment. Normalization of the mediotemporal hypermetabolism after immunotherapy in our LGI1-AE group at approximately 6 months follow-up is in concordance with the few earlier studies\(^9,19\) with follow-up intervals of 2–9 months.\(^9,19\) FDG-PET abnormalities in the acute phase of illness may represent an earlier pathophysiologic correlate of the long-term hippocampal atrophy seen in some patients with LGI1-AE.\(^39\) We also observed olfactory gyrus hypermetabolism in LGI1-AE. We hypothesize that the olfactory hypermetabolism may be functionally associated with mediotemporal hypermetabolism through the limbic system.

FDG-PET was more sensitive than MRI in detecting abnormalities in LGI1-AE in our study, similar to previous studies.\(^9,35\) Furthermore, MTL hypermetabolism associated with the degree of clinical impairment at initial presentation. Thus, FDG-PET may provide clinically relevant information for detecting MTL dysfunction in LGI1-AE. Although useful to distinguish LGI1-AE group from NCs, semiquantitative evaluation of mediotemporal metabolism alone did not help distinguish LGI1-AE from other types of AE.

In addition to basal ganglia and MTL changes, we found significant hypometabolism in widespread cortical brain regions, particularly in inferior frontal and parietal lobes. Neocortical hypometabolism may be a result of functional impairment propagated along cortical and subcortical networks, arising from the sites of primary abnormalities in MTL and basal ganglia.\(^29\) Significant reductions in brain connectivity involving inferior frontal gyrus, anterior and posterior cingulate gyri, several regions of the default mode network (DMN), and higher visual networks have been previously demonstrated in patients with LGI1-AE using resting-state fMRI.\(^29,30\) Recovery of neocortical hypometabolism in short term after immunotherapy and its association with clinical improvement in our study supports a role of functional disconnection in the pathogenesis of this PET finding and also underscores their clinical relevance in the acute phase. On the other hand, occipital hypometabolism may be a compensatory mechanism in response to MTL and DMN dysfunction in patients with LGI1-AE during the acute/early phase of the illness. A similar pattern of occipital hypometabolism has been reported as a compensatory phenomenon in patients with amnestic mild cognitive impairment.\(^40\) Moreover, while LGI1 is highly expressed in basal ganglia and hippocampal subfields, weak expression of LGI1 is also reported in inner layers of cerebral cortex.\(^28,41\) Future studies using ultra-high-resolution PET scanners may help delineate the extent of hypometabolism or localized hypermetabolism within cortical layers in patients with LGI1-AE, which may be undetectable on current PET scanners owing to their more limited spatial resolution.

Previous longitudinal studies have shown that long-term recovery of cognitive impairment lagged resolution of seizures\(^8\) in patients with LGI1-AE. Specifically, on long-term follow-up of more than 2 years, approximately 70% of patients with LGI1-AE experienced mild-to-moderate residual cognitive impairment in a European cohort,\(^8\) similar to our study. Although a detailed neuropsychologic evaluation\(^42\) was not performed in our study, clinical disability at long-term follow-up in our cohort was primarily driven by cognitive symptoms. The trend for the association between longer delay from symptom onset to baseline PET and worse long-term outcome underlines the importance of prompt diagnosis in LGI1-AE. Of interest, reduced metabolic activity in limbic/paralimbic cortical regions at the time of presentation was associated with the ultimate mRS scores at long-term follow-up in our study (median duration 20 months). Mechanistically, this may mean that in some patients LGI1-AE, acute cortical hypometabolism may lead to more persistent structural injury and needs to be evaluated in future studies. Indeed, whole brain atrophy and gray matter reduction of glutamine/glutamate ratio (on magnetic resonance spectroscopy) have been reported on long-term follow-up (mean duration 33 months),\(^43\) but no previous data regarding long-term prognostic implications of FDG-PET are available in LGI1-AE.

Another interesting finding in our study is that pallidum and caudate also showed increased metabolic activity when compared with NCs, although this is not often appreciated on visual analyses owing to a lower metabolic rate in the pallidum when compared with other basal ganglia structures.

We acknowledge several limitations to our study. Ours is a single-center study with limited sample sizes, and there is clearly a need for larger, prospective, multicenter FDG-PET imaging studies in LGI1-AE and other autoimmune encephalitides.\(^44\) Regarding using semiquantitative indices for differential diagnosis, apart from scanner differences, effects of previous treatment would need to be considered. Immunosuppressive treatment initiated before initial FDG-PET may be associated with false-negative P/Mi values based on these cutoffs. In addition, we are reporting a case with APS showing striatal hypermetabolism and a high P/Mi value of 1.57. Striatal hypermetabolism in systemic lupus erythematosus–associated chorea has been reported,\(^45\) but semiquantitative putaminal hypermetabolism in APS has not been reported earlier. Furthermore, neurologic conditions disproportionately affecting midbrain, such as progressive supranuclear palsy,\(^46\) may demonstrate high P/Mi values because of low midbrain metabolism and should also be considered in differential diagnosis. FDG-PET scans may be considered investigational\(^44\) and may not be readily available in all hospitals, and patients may require referral to a tertiary care center to undergo FDG-PET. Future studies should combine neuropsychologic testing with immunology, multimodality imaging including longitudinal FDG-PET, structural and functional MRI, and electrophysiologic measurements to further elucidate the pathophysiology of LGI1-AE and to guide clinical diagnostic and therapeutic decision-making.

In conclusion, our data suggest that metabolic abnormalities in LGI1-AE extend beyond putamen and mediotemporal lobe into other subcortical and cortical regions and that
semiquantitative FDG-PET may aid in differential diagnosis and longitudinal follow-up of patients with LGI1-AE. Further prospective, longitudinal, multicenter studies with larger patient populations are warranted to confirm these findings.

**Acknowledgment**
The authors thank Mr. Jon Hainer for his assistance in performing database searches.

**Study Funding**
E. Rissanen has received a Sigrid Juselius Fellowship Grant. T. Singhal has received research funding from Nancy Davis Foundation’s “Race to Erase MS” program, Ann Romney Center for Neurologic Diseases, Harvard Neuro-Discovery Center, National Multiple Sclerosis Society, Department of Defense, and Water Cove Charitable Foundation. Funding agencies did not have any role in performance of the research or preparation of the manuscript.

**Disclosure**
The authors report no conflicts of interest relevant to this work. Go to Neurology.org/NN for full disclosures.

**Publication History**
Received by Neurology: Neuroimmunology & Neuroinflammation June 29, 2021. Accepted in final form December 14, 2021.

---

**Appendix Authors**

<table>
<thead>
<tr>
<th>Name</th>
<th>Location</th>
<th>Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eero Rissanen, MD, PhD</td>
<td>PET Imaging Program in Neurologic Diseases, Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School; Brigham Multiple Sclerosis Center, Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School</td>
<td>Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data; and analysis or interpretation of data</td>
</tr>
<tr>
<td>Kelsey Carter, MSN, CNP</td>
<td>PET Imaging Program in Neurologic Diseases, Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School</td>
<td>Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data; and analysis or interpretation of data</td>
</tr>
<tr>
<td>Steven Cicero, BS</td>
<td>PET Imaging Program in Neurologic Diseases, Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School</td>
<td>Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data; and analysis or interpretation of data</td>
</tr>
<tr>
<td>John Ficke, BA</td>
<td>PET Imaging Program in Neurologic Diseases, Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School</td>
<td>Drafting/revision of the article for content, including medical writing for content, and major role in the acquisition of data</td>
</tr>
<tr>
<td>Marie Kijewski, DSc</td>
<td>Division of Nuclear Medicine and Molecular Imaging (M.K.), Department of Radiology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA</td>
<td>Drafting/revision of the article for content, including medical writing for content, and analysis or interpretation of data</td>
</tr>
<tr>
<td>Mi-Ae Park, PhD</td>
<td>Medical Physics Section, Radiology Department, University of Texas Southwestern Medical Center, Dallas, TX</td>
<td>Drafting/revision of the article for content, including medical writing for content, and analysis or interpretation of data</td>
</tr>
<tr>
<td>Joseph Kijewski, BS</td>
<td>Department of Neurology, Brigham and Women's Hospital, Boston, MA</td>
<td>Drafting/revision of the article for content, including medical writing for content, and major role in the acquisition of data</td>
</tr>
<tr>
<td>Emily Stern, MD</td>
<td>Ceretype Neuromedicine, Cambridge, MA</td>
<td>Drafting/revision of the article for content, including medical writing for content, and analysis or interpretation of data</td>
</tr>
<tr>
<td>Tanuja Chitnis, MD</td>
<td>Brigham Multiple Sclerosis Center, Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA</td>
<td>Drafting/revision of the article for content, including medical writing for content, and analysis or interpretation of data</td>
</tr>
<tr>
<td>David Silbersweig, MD</td>
<td>Functional Neuroimaging Laboratory, Department of Psychiatry, Brigham and Women's Hospital and Harvard Medical School, Boston, MA</td>
<td>Drafting/revision of the article for content, including medical writing for content, and analysis or interpretation of data</td>
</tr>
<tr>
<td>Howard L. Weiner, MD</td>
<td>Brigham Multiple Sclerosis Center, Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA</td>
<td>Drafting/revision of the article for content, including medical writing for content, and analysis or interpretation of data</td>
</tr>
</tbody>
</table>
References
Cortical and Subcortical Dysmetabolism Are Dynamic Markers of Clinical Disability and Course in Anti-LGI1 Encephalitis
Eero Rissanen, Kelsey Carter, Steven Cicero, et al.
*Neurol Neuroimmunol Neuroinflamm* 2022;9;
DOI 10.1212/NXI.0000000000001136

This information is current as of January 28, 2022

| Updated Information & Services | including high resolution figures, can be found at: http://nn.neurology.org/content/9/2/e1136.full.html |
| References | This article cites 45 articles, 7 of which you can access for free at: http://nn.neurology.org/content/9/2/e1136.full.html#ref-list-1 |
| Subspecialty Collections | This article, along with others on similar topics, appears in the following collection(s): Class III http://nn.neurology.org/cgi/collection/class_iii PET http://nn.neurology.org/cgi/collection/pet |
| Permissions & Licensing | Information about reproducing this article in parts (figures,tables) or in its entirety can be found online at: http://nn.neurology.org/misc/about.xhtml#permissions |
| Reprints | Information about ordering reprints can be found online: http://nn.neurology.org/misc/addir.xhtml#reprintsus |